title: Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
abstract: Angiogenesis is an attractive target for cancer therapy, due to its central position in tumor growth and development. Vascular Endothelial Growth Factor (VEGF) and its receptors (VEGFRs) play a key role in the angiogenic process. A promising strategy for targeting VEGF-mediated angiogenesis is RNA interference (RNAi) using short interfering RNA (siRNA). However, for efficacious RNAi a well-designed siRNA delivery system is crucial. Liposome-Polycation-DNA (LPD) particles form a promising system for siRNA delivery to tumors. In order to target angiogenic endothelial cells, LPD particles may be modified with a targeting ligand, such as a cyclic Arg-Gly-Asp (RGD) peptide that specifically binds to integrins expressed on tumor-associated endothelial cells. In the current study, RGD-targeted PEGylated LPD particles containing VEGFR-2 siRNA were prepared and optimized with respect to their size and charge by varying protamine content, carrier DNA content for stronger complexation, and PEGylation density. The size of the optimized particles was around 200 nm and the ζ-potential was approximately +20 mV. The uptake and silencing efficacy of the RGD-targeted PEGylated LPD particles were evaluated in H5V cells (murine endothelial cells) and Human Umbilical Vein Endothelial cells (HUVECs). When compared to non-targeted LPD particles, enhanced uptake and silencing of VEGFR-2 expression was observed for RGD-targeted PEGylated LPD particles. In conclusion, the RGD-targeted PEGylated LPD particles containing VEGFR-2 siRNA presented here may be a promising approach for targeting VEGF-mediated angiogenesis in cancer therapy.
authors: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. P.Vader@uu.nl
authors: P
authors: P
authors: Vader
authors: B J
authors: BJ
authors: Crielaard
authors: S M
authors: SM
authors: van Dommelen
authors: R
authors: R
authors: van der Meel
authors: G
authors: G
authors: Storm
authors: R M
authors: RM
authors: Schiffelers
mesh_terms: D000818:Animals; D015153:Blotting, Western; D018929:Cell Culture Techniques; D004247:DNA / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D042783:Endothelial Cells / Q000378:metabolism* / Q000473:pathology; D020868:Gene Silencing; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D008081:Liposomes; D051379:Mice; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology; D010316:Particle Size; D011073:Polyamines / Q000737:chemistry*; D000071228:Polyelectrolytes; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D004247:DNA; D004337:Drug Carriers; D008081:Liposomes; D011073:Polyamines; D000071228:Polyelectrolytes; D034741:RNA, Small Interfering; D040301:Vascular Endothelial Growth Factor Receptor-2; C427203:calf thymus DNA